Medscape Medical News > Conference News > ESC 2024 Sue Hughes September 05, 2024 LONDON — Two new trials have confirmed that time of day does not matter when it comes to taking antihypertensive medication. Both the BedMed and BedMed-Frail trials, presented at the European Society of Cardiology (ESC) Congress, showed no difference in death...
Category: <span>Pharmaceutical Updates</span>
Post
FDA Approves JAK Inhibitor Deuruxolitinib for Alopecia Areata
The US Food and Drug Administration (FDA) has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib for the treatment of adults with severe alopecia areata. The development, which was announced in a July 25, 2024, news release from the drug’s manufacturer Sun Pharma, is based on data from two pivotal randomized, double-blind, placebo-controlled phase 3...
Post
New study provides insight to why COVID vaccines hit some harder than others
September 4, 2024 by Anna Zarra Aldrich, University of Connecticut Students receiving the COVID 19 vaccine at Hawley Armory on April 8, 2021. The rollout of the vaccines across the state in the spring helped set up a return to a more familiar university experience. Credit: Sean Flynn/UConn PhotoWhen you got the SARS-CoV2 vaccine to...
Post
UK Restrictions on Valproate: Should the US Follow Suit?
Medscape Medical News Deborah Brauser August 23, 2024 As experts voice concerns over new UK guidelines that restrict valproate use in women and men younger than 55 years owing to safety risks, the question arises: Should the US consider updating its own guidelines in response? On January 31, the UK Medicines and Healthcare products Regulatory...
Post
Nalmefene Auto-Injector: Concerns About the New Opioid Overdose Antidote Explained
Medscape Medical News > Features Patrice Wendling August 21, 2024 The first nalmefene hydrochloride (HCl) auto-injector (Zurnai) brings a new tool to the fight against the opioid overdose epidemic but is not without controversy. As reported earlier this month, the US Food and Drug Administration (FDA) approved Purdue Pharma’s abbreviated new drug application for a...
Post
Weight loss drug’s heart benefits extend to people with heart failure
News Release 22-Aug-2024 The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new UCL-led study Peer-Reviewed PublicationUniversity College London The anti-obesity medication semaglutide may help to prevent heart attacks and...
Post
Inhaler misuse leads to mismanagement of COPD symptoms, increased exacerbations
News Release 20-Aug-2024 Patients need additional education on proper inhaler use to improve outcomes Peer-Reviewed PublicationCOPD Foundation MIAMI (August 20, 2024) – Inhaler misuse leading to inadequate medication delivery impacts a person’s ability to manage symptoms of chronic obstructive pulmonary disease (COPD), and additional education about proper inhaler use is needed to improve health outcomes,...
Post
MNT Investigates: Do ulcerative colitis treatments reduce the risk of heart attack?
Research has linked ulcerative colitis (UC) to an increased risk of heart disease, including heart attack and stroke. Some UC treatments may help reduce the risk of heart problems, though more research is necessary. UC refers to chronic inflammation in the inner lining of the large intestine. People with UC may also develop inflammation in...
Post
‘Remarkable’ Weight Loss Seen With Novel Oral Combination That Is Safe and Tolerable in Phase 1 Study
Medscape Medical News > Conference News > EASD 2024 Becky McCall September 12, 2024 MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the European Association for the Study of Diabetes...
Post
Ignore antifungal resistance in fungal disease at your peril, warn scientists
September 13, 2024 by University of Amsterdam Candida albicans. Credit: Wikipedia.Without immediate action, humanity will potentially face further escalation in resistance in fungal disease, a group of scientists from across the world has warned. The commentary—published in The Lancet—was coordinated by scientists at The University of Manchester, the Westerdijk Institute and the University of Amsterdam....